WEBULL

Did FDA’s First Oral PCSK9 Approval Just Recast Merck’s (MRK) Pipeline-Driven Growth Narrative?

Simply Wall St · 1d ago
  • Earlier this week, Merck & Co. received U.S. FDA approval for LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, after Phase 3 trials showed substantial LDL cholesterol reductions in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
  • This first-in-class oral PCSK9 pill could reshape cholesterol management by offering an easier alternative to injectables for a very large patient population.
  • Now we’ll examine how launching the first oral PCSK9 inhibitor may influence Merck’s pipeline-driven investment narrative and long-term growth mix.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Merck Investment Narrative Recap

To own Merck today, you need to believe its pipeline can steadily rebalance the business as KEYTRUDA approaches loss of exclusivity and pricing pressure stays elevated. The LIPFENDRA approval strengthens the cardiometabolic side of that story and is a visible near term catalyst, but it does not remove key risks like potential GARDASIL softness in China or broader drug pricing reform; it simply gives Merck another tangible proof point that the “20 new growth drivers” plan is taking shape.

Among recent developments, the Illumina Billion Cell Atlas alliance is especially relevant beside LIPFENDRA. While LIPFENDRA shows how Merck can convert late stage assets into products, the Atlas highlights how Merck is trying to keep that pipeline full, using large scale functional genomics and AI driven discovery with peers like AstraZeneca and Lilly. Together, they frame the core catalyst for the stock: whether this kind of R&D infrastructure can consistently produce the next wave of post KEYTRUDA therapies.

Yet, despite this progress, investors should still watch how potential pricing pressure on new drugs like LIPFENDRA could...

Read the full narrative on Merck (it's free!)

Merck's narrative projects $74.6 billion revenue and $22.3 billion earnings by 2029.

Uncover how Merck's forecasts yield a $132.78 fair value, a 4% upside to its current price.

Exploring Other Perspectives

MRK 1-Year Stock Price Chart
MRK 1-Year Stock Price Chart

Some of the lowest analyst forecasts painted a far more cautious picture, with revenue only reaching about US$71.9 billion and earnings US$22.3 billion by 2029, and they worried that reliance on a few flagship drugs could leave Merck exposed if products like LIPFENDRA or other new launches fall short, so it is worth comparing those more pessimistic expectations with how this approval might eventually reshape both the risk of pricing pressure and the opportunity in Merck's broader pipeline.

Explore 8 other fair value estimates on Merck - why the stock might be worth as much as 72% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.